TY - JOUR
T1 - Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer
AU - Rolfo, Christian
AU - Bazan, Viviana
AU - Caruso, Stefano
AU - Cicero, Giuseppe
AU - Fanale, Daniele
AU - Russo, Antonio
AU - Hong, David S.
AU - Piha-Paul, Sarina A.
AU - Tsimberidou, Apostolia M.
AU - Pauwels, Patrick
AU - Van Meerbeeck, Jan P.
AU - Giovannetti, Elisa
N1 - Publisher Copyright:
© 2014 Bentham Science Publishers.
PY - 2014/9/1
Y1 - 2014/9/1
N2 - Despite recent advances in understanding the cancer signaling pathways and in developing new therapeutic strategies, non-small cell lung cancer (NSCLC) shows grim prognosis and high incidence of recurrence. Insufficient disruption of oncogenic signaling and drug resistance are the most common causes of tumor recurrence. Drug resistance, intrinsic or acquired, represents a main obstacle in NSCLC therapeutics by limiting the efficacy both of conventional chemotherapeutic compounds and new targeted agents. Therefore, novel and more innovative approaches are required for treatment of this tumor. MicroRNAs (miRNAs) are a family of small non-coding RNAs that regulate gene expression by sequence-specific targeting of mRNAs causing mRNA degradation or translational repression. Accumulating evidence suggests that impairment of candidate miRNAs may be involved in the acquisition of tumor cell resistance to conventional chemotherapy and novel biological agents by affecting the drug sensitivity of cancer cells. The modulation of these miRNAs, using antagomiRs or miRNA mimics, can restore key gene networks and signaling pathways, and optimize anticancer therapies by inhibition of tumor cell proliferation and increasing the drug sensitivity. Therefore, miRNA-based therapeutics provides an attractive anti-tumor approach for developing new and more effective individualized therapeutic strategies, improving drug efficiency, and for predicting the response to different anticancer drugs. In this review, we present an overview on the role of miRNAs in resistance mechanisms of NSCLC, discussing the main studies on the aberrations in apoptosis, cell cycle and DNA damage repair pathways, as well as in novel drug targets.
AB - Despite recent advances in understanding the cancer signaling pathways and in developing new therapeutic strategies, non-small cell lung cancer (NSCLC) shows grim prognosis and high incidence of recurrence. Insufficient disruption of oncogenic signaling and drug resistance are the most common causes of tumor recurrence. Drug resistance, intrinsic or acquired, represents a main obstacle in NSCLC therapeutics by limiting the efficacy both of conventional chemotherapeutic compounds and new targeted agents. Therefore, novel and more innovative approaches are required for treatment of this tumor. MicroRNAs (miRNAs) are a family of small non-coding RNAs that regulate gene expression by sequence-specific targeting of mRNAs causing mRNA degradation or translational repression. Accumulating evidence suggests that impairment of candidate miRNAs may be involved in the acquisition of tumor cell resistance to conventional chemotherapy and novel biological agents by affecting the drug sensitivity of cancer cells. The modulation of these miRNAs, using antagomiRs or miRNA mimics, can restore key gene networks and signaling pathways, and optimize anticancer therapies by inhibition of tumor cell proliferation and increasing the drug sensitivity. Therefore, miRNA-based therapeutics provides an attractive anti-tumor approach for developing new and more effective individualized therapeutic strategies, improving drug efficiency, and for predicting the response to different anticancer drugs. In this review, we present an overview on the role of miRNAs in resistance mechanisms of NSCLC, discussing the main studies on the aberrations in apoptosis, cell cycle and DNA damage repair pathways, as well as in novel drug targets.
KW - Chemotherapy
KW - Lung cancer
KW - Oncogenic pathways
KW - Resistance
KW - Targeted agents
KW - microRNA
UR - http://www.scopus.com/inward/record.url?scp=84907170770&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907170770&partnerID=8YFLogxK
U2 - 10.2174/1389201015666140519123219
DO - 10.2174/1389201015666140519123219
M3 - Article
C2 - 24846062
AN - SCOPUS:84907170770
SN - 1389-2010
VL - 15
SP - 475
EP - 485
JO - Current Pharmaceutical Biotechnology
JF - Current Pharmaceutical Biotechnology
IS - 5
ER -